Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

(2013) S. E. Pratt et al.   CLINICAL CANCER RESEARCH

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

(2013) F. E. Stuurman et al.   INVESTIGATIONAL NEW DRUGS

Abstract B31: Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment carboxylesterase II expression in solid tumor biopsies

(2012) T. R. Holzer et al.   CLINICAL CANCER RESEARCH

Abstract B36: Identification of carboxylesterase 2 as a hydrolase that cleaves the prodrug of gemcitabine LY2334737

(2012) S. E. Pratt et al.   CLINICAL CANCER RESEARCH

Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications

(2012) Elodie Moysan et al.   MOLECULAR PHARMACEUTICS

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2011) Stijn L.W. Koolen et al.   CLINICAL CANCER RESEARCH

Quantification of Gemcitabine Incorporation into Human DNA by LC/MS/MS as a Surrogate Measure for Target Engagement

(2010) Enaksha R. Wickremsinhe et al.   ANALYTICAL CHEMISTRY

Prolonged intrahepatic cholestasis after exposure to loxoprofen

(2009) Takeshi Ichikawa et al.   CLINICAL THERAPEUTICS

Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine

(2009) David M. Bender et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

(2008) S. A. Veltkamp et al.   CLINICAL CANCER RESEARCH

New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine

(2008) S. A. Veltkamp et al.   MOLECULAR CANCER THERAPEUTICS